We have set up this channel to give you convenient access to the latest research in the area of Cancer-associated thrombosis (CAT) by providing a customised feed of abstracts of clinical papers published on PubMed. The combination of search terms providing the feed below is 'cancer AND thrombosis'. This channel is sorted chronologically. To see more information about a given paper, click the ‘Preview Abstract’ button below, and this will reveal an expanded abstract.
PMID: 32734452 [PubMed - as supplied by publisher]
Along with cancer, cardiovascular and cerebrovascular diseases remain by far the most common causes of death. Heart attacks and strokes are diseases in which platelets play a role, through activation on ruptured plaques and subsequent thrombus formation. Most platelet agonists activate platelets via G protein-coupled receptors (GPCRs), which make these receptors ideal targets for many antiplatelet drugs. However, little is known about the mechanisms that provide feedback...
Myeloproliferative neoplasms (MPNs) are associated with the fewest number of mutations among known cancers. The mutations propelling these malignancies are phenotypic drivers providing an important implement for diagnosis, treatment response monitoring, and gaining insight into the disease biology. The phenotypic drivers of Philadelphia chromosome negative MPN include mutations in JAK2, CALR, and MPL. The most prevalent driver mutation JAK2V617F can cause disease entities...
Unprovoked venous thromboembolism (VTE) can be the first sign of an occult cancer. The rate of occult cancer detection within 12 months of a newly diagnosed unprovoked VTE is approximately 5%. Therefore, it is appealing for clinicians to screen patients with unprovoked VTE for occult cancer, as it could potentially decrease cancer-related mortality and morbidity and improve quality of life. However, several randomized controlled trials have failed to report that an extensive...
BACKGROUND Pulmonary vein thrombosis (PVT) is a rare clinical entity. Etiologies include malignancy, hyper-viscosity syndromes, and other etiologies. Patients may present with dyspnea, cough, or hemoptysis. CASE REPORT We present a case of a 64-year-old man with a history of metastatic lung cancer diagnosed with PVT through transesophageal echocardiography (TEE) and complicated by 2 cerebrovascular accidents. The patient had a complicated hospital course and died later due...
OBJECTIVE: To report a single-center experience with thrombolytic therapy using recombinant tissue plasminogen activator (rt-PA) in preterm neonates with severe thrombotic events, in terms of thrombus resolution and bleeding complications.
STUDY DESIGN: This retrospective study included 21 preterm neonates with severe venous thrombotic events admitted to the neonatal intensive care unit, identified in our pharmacy database from January 2001 to December 2016, and...
PURPOSE: Injection of botulinum toxin into the internal anal sphincter is a well-documented intervention to reduce anal hypertonia in the treatment of anal fissures. In patients receiving chemotherapy, painful anal conditions are frequent, secondary to change in bowel habits and reduced immunity. However, injection of botulinum toxin is often not offered due to fear of complications.
METHODS: In this retrospective longitudinal observational study, performed in a...
Extracorporeal membrane oxygenation (ECMO) is an extracorporeal circulation used to manage patients with severe circulatory or respiratory failure. It is associated with both high bleeding and thrombosis risks, mainly as a result of biomaterial/blood interface phenomena, high shear stress, and complex inflammatory response involving the activation of coagulation and complement systems, endothelial cells, leukocytes, and platelets. Besides their critical role in hemostasis,...
BACKGROUND: The role of antithrombotic chemoprophylaxis in prevention of venous thromboembolism (VTE) in laparoscopic surgery for gastric and colorectal malignancies is unknown. This study compared the addition of enoxaparin following intermittent pneumatic compression (IPC) with IPC alone in patients undergoing laparoscopic surgery for gastrointestinal malignancy.
METHODS: In this multicentre RCT, eligible patients were older than 40 years and had a WHO performance...
INTRODUCTION: Polycythemia vera (PV), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 mutation. Patients are at increased risk of thrombohemorrhagic events, and progression to myelofibrosis or acute leukemia. Current treatments include aspirin, phlebotomy, and cytoreductive drugs (most commonly hydroxyurea). Givinostat is a potent, class I/II histone deacetylase (HDAC) inhibitor that is in phase I/II...
ICTHIC Lunchtime Symposium April 2018: Dr Marc Carrier
ICTHIC Lunchtime Symposium April 2018: Alexander Cohen
ICTHIC Lunchtime Symposium April 2018: Dr Florian Langer MD
ICTHIC Lunchtime Symposium April 2018: Dr Luis Jara-Palomares, MN, PhD
Structured Modules in CAT
Nov 21, 2016
Oct 28, 2016
Oct 27, 2016
Sep 29, 2016
Please fill out the following form with your login credentials:
This website is intended to provide non-promotional, educational information to an international healthcare professional audience only.
You have indicated that you are not a healthcare professional and therefore, do not have access to this site.Please click here to continue browsing
This website is owned by LEO Pharma.
Cookies by themselves cannot be used to discover the identity of the user, and they do not in any way damage your computer.
We use a Google Analytics cookie, further information can be seen here:: Google Analytics Cookie Usage
The browsers of most computers, smartphones and other web-enabled devices are typically set up to accept cookies. If you wish to amend your cookie preferences for this site or any other websites, you can do this through your browser settings. Your browser's 'help' function will tell you how to do this.
However, please remember that cookies are often used to enable and improve certain functions on our site. If you therefore choose to disable the cookies that we use, this may impact your experience while on www.cathrombosis.com, for example, you may not be able to visit certain areas of the site and you may not receive personalised information.
If you use different devices to view and access the site (e.g. your computer, smartphone, tablet etc.) you will need to ensure that each browser on each device is adjusted to suit your cookie preferences.
For more information on how to disable cookies, visit www.allaboutcookies.org